YORVIPATH Drug Scores FDA Patent Review Extension
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for YORVIPATH, a human drug product, so its patent can be extended. This means the company behind YORVIPATH gets more time to protect their invention and keep competitors at bay. If you’re in the drug business, watch for these updates—they can affect when new versions hit the market and how long the original maker stays in charge.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA OKs Patent-Extension Review For YORVIPATH
The FDA has determined the regulatory review period for YORVIPATH so the drug’s maker can seek a patent extension from the U.S. Patent and Trademark Office. This gives the company extra time to protect its invention and can keep competitors from selling the same drug while the extension is in effect.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in